Survivin in Adrenocortical Tumors – Pathophysiological Implications and Therapeutic Potential

 

 Buy Article Permissions and Reprints

Abstract

Treatment options for adrenocortical carcinoma (ACC) are very limited. In other solid tumors, small vaccination trials targeting the anti-apoptotic molecule survivin suggested immunological and clinical benefit in selected patients. Therefore, we investigated whether survivin might be a suitable target for immunotherapy in ACC. Survivin mRNA and protein expression was assessed in adrenal tissue specimens [by real-time-PCR in 29 ACC, 24 adrenocortical adenomas (ACA) and 12 normal adrenal glands; by immunohistochemistry in 167 ACCs, 15 ACA, and 5 normal adrenal glands]. Expression was correlated with clinical outcome using Kaplan–Meier and Cox regression analyses. The anti-apoptotic role of survivin was investigated in the SW13 ACC cell line using survivin siRNA. The presence of spontaneous survivin specific T-cells in peripheral blood was assessed by FACS dextramere staining in 29 ACC patients in comparison to healthy controls. Survivin mRNA in ACC was significantly overexpressed when compared with ACA or normal adrenal glands. Immunohistochemistry confirmed survivin protein expression in 97% of the ACCs. In 83% of samples, staining was moderate or high and clinical outcome in this subgroup showed a trend towards poorer prognosis [hazard ratio for death 2.28 (95% CI 0.99–5.28); p=0.053]. Survivin knockdown in SW-13 cell significantly increased the rate of apoptosis. Finally, spontaneous survivin-reactive T cells were detectable in 3 of 29 ACC patients. In conclusion, our data suggest that survivin could play an important role in the anti-apoptotic mechanisms in ACC and provide first hints that targeting survivin might be an interesting new therapeutic approach in this rare disease.

• References

• 1 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921
  CrossrefPubMedGoogle Scholar
• 2 Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320
  PubMedGoogle Scholar
• 3 Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584
  CrossrefPubMedGoogle Scholar
• 4 Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005
  CrossrefPubMedGoogle Scholar
• 5 Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65: 4881-4887
  CrossrefPubMedGoogle Scholar
• 6 Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Clin Breast Cancer 2011; 11: 129-134
  CrossrefPubMedGoogle Scholar
• 7 Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer 2011; 10: 188-193
  CrossrefPubMedGoogle Scholar
• 8 Altieri DC. Targeting survivin in cancer. Cancer Lett 2012; Mar 9 [Epub ahead of print]
  PubMedGoogle Scholar
• 9 Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res 2011; 17: 3716-3726
  CrossrefPubMedGoogle Scholar
• 10 Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, Greenberger LM, Horak ID, Grupp SA, Teachey DT, Raetz EA, Carroll WL. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271-279
  CrossrefPubMedGoogle Scholar
• 11 Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Muschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011; 118: 2191-2199
  CrossrefPubMedGoogle Scholar
• 12 Zhao X, Ogunwobi OO, Liu C. Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS One 2011; 6: e21980
  CrossrefPubMedGoogle Scholar
• 13 Croce M, Meazza R, Orengo AM, Fabbi M, Borghi M, Ribatti D, Nico B, Carlini B, Pistoia V, Corrias MV, Ferrini S. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 2008; 57: 1625-1634
  CrossrefPubMedGoogle Scholar
• 14 Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61: 869-872
  PubMedGoogle Scholar
• 15 Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006; 24: 5725-5734
  CrossrefPubMedGoogle Scholar
• 16 Grube M, Moritz S, Obermann EC, Rezvani K, Mackensen A, Andreesen R, Holler E. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 2007; 13: 1053-1060
  CrossrefPubMedGoogle Scholar
• 17 Hadrup SR, Gehl J, Sorensen RB, Geertsen PF, Straten PT, Andersen MH. Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther 2006; 5: 480-482
  CrossrefPubMedGoogle Scholar
• 18 Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World J Surg 2006; 30: 872-878
  CrossrefPubMedGoogle Scholar
• 19 Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14: 13-28
  CrossrefPubMedGoogle Scholar
• 20 Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 2011; 7: 323-335
  CrossrefPubMedGoogle Scholar
• 21 Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M, Baudin E. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007; 92: 148-154
  PubMedGoogle Scholar
• 22 Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008; 113: 3130-3136
  CrossrefPubMedGoogle Scholar
• 23 Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009 115. 243-250
  PubMedGoogle Scholar
• 24 Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M, Kroiss M, Jurowich C, Langer P, Oelkers W, Spahn M, Willenberg HS, Mader U, Allolio B, Fassnacht M. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int 2010; 107: 885-891
  PubMedGoogle Scholar
• 25 Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB, Rowland C, Young Jr WF, van Heerden JA. Adrenocortical carcinoma: surgical progress or status quo?. Arch Surg 2001; 136: 543-549
  CrossrefPubMedGoogle Scholar
• 26 Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Maaa Q, Jaaa W, Willenberg HS, Beuschlein F, Fottner C, Brix D, Fenske W, Reibetanz J, Allolio B, Fassnacht M. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab 2012; in revision
  PubMedGoogle Scholar
• 27 Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380
  CrossrefPubMedGoogle Scholar
• 28 Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer – a recurring controversy. J Clin Endocrinol Metab 2008; 93: 3730-3732
  CrossrefPubMedGoogle Scholar
• 29 Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A. Adjuvant mitotane for adrenocortical cancer – working through uncertainty. J Clin Endocrinol Metab 2009; 94: 1879-1880
  CrossrefPubMedGoogle Scholar
• 30 Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?. Clin Endocrinol (Oxf) 2010; 73: 561-565
  CrossrefPubMedGoogle Scholar
• 31 Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B, Terzolo M. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 2010; 28: e401-e402 authors’ reply e403
  CrossrefPubMedGoogle Scholar
• 32 Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Muller HH, Skogseid B. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197
  CrossrefPubMedGoogle Scholar
• 33 Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, Dumont F, Dechamps F, Caramella C, Chanson P, Lanoy E, Borget I, Schlumberger M. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?. Horm Cancer 2011; 2: 363-371
  CrossrefPubMedGoogle Scholar
• 34 Volante M, Sperone P, Bollito E, Frangipane E, Rosas R, Daffara F, Terzolo M, Berruti A, Papotti M. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol 2006; 19: 1563-1569
  CrossrefPubMedGoogle Scholar
• 35 Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 2010; 95: E161-E171
  CrossrefPubMedGoogle Scholar
• 36 Fenske W, Volker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Muller-Hermelink HK, Allolio B, Fassnacht M. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 2009; 16: 919-928
  CrossrefPubMedGoogle Scholar
• 37 Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I, Audebourg A, Royer B, Sbiera S, Vacher-Lavenu MC, Dousset B, Bertagna X, Allolio B, Bertherat J, Tissier F. Beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011; 17: 328-336
  CrossrefPubMedGoogle Scholar
• 38 Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 2010; 17: 797-807
  CrossrefPubMedGoogle Scholar
• 39 Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 2009; 16: 907-918
  CrossrefPubMedGoogle Scholar
• 40 Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, Sbiera S, Daffara F, Sperone P, Scagliotti G, Allolio B, Papotti M, Berruti A. Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clin Cancer Res 2012; 18: 3452-3461
  CrossrefPubMedGoogle Scholar
• 41 Bussey KJ, Demeure MJ. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment. Future Oncol 2009; 5: 641-655
  CrossrefPubMedGoogle Scholar
• 42 Feller N, Hoekman K, Kuiper CM, Linn SC, Verheul HM, Wolthers BG, Popp-Snijders C, Pinedo HM. A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. Clin Cancer Res 1997; 3: 389-394
  PubMedGoogle Scholar
• 43 Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 1990; 50: 5488-5496
  PubMedGoogle Scholar
• 44 Leibowitz A, McCombs III WB, Johnston D, McCoy CE, Stinson JC. New human cancer cell culture lines. I. SW 13, small cell carcinoma of the adrenal cortex. Journal of the National Cancer Institute 1973; 51: 691-697
  PubMedGoogle Scholar
• 45 Kroiss M, Reuss M, Kuhner D, Johanssen S, Beyer M, Zink M, Hartmann MF, Dhir V, Wudy SA, Arlt W, Sbiera S, Allolio B, Fassnacht M. Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells. Front Endocrinol (Lausanne) 2011; 2: 27
  PubMedGoogle Scholar
• 46 Adam P, Hahner S, Hartmann M, Heinrich B, Quinkler M, Willenberg HS, Saeger W, Sbiera S, Schmull S, Voelker HU, Strobel P, Allolio B, Fassnacht M. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol 2010; 23: 1596-1604
  CrossrefPubMedGoogle Scholar
• 47 Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009; 15: 668-676
  CrossrefPubMedGoogle Scholar
• 48 Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384
  Google Scholar
• 49 Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005; 436: 807-811
  CrossrefPubMedGoogle Scholar
• 50 Sbiera S, Wortmann S, Fassnacht M. Dendritic cell based immunotherapy – a promising therapeutic approach for endocrine malignancies. Horm Metab Res 2008; 40: 89-98
  Article in Thieme ConnectPubMedGoogle Scholar
• 51 Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54
  CrossrefPubMedGoogle Scholar
• 52 Koch CA, Vortmeyer AO, Diallo R, Poremba C, Giordano TJ, Sanders D, Bornstein SR, Chrousos GP, Pacak K. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 2002; 146: 381-388
  CrossrefPubMedGoogle Scholar
• 53 Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005; 11: 1474-1482
  CrossrefPubMedGoogle Scholar
• 54 Yang Z, Wang L, Wang H, Shang X, Niu W, Li J, Wu Y. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency. Mol Immunol 2008; 45: 1674-1681
  CrossrefPubMedGoogle Scholar
• 55 Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 2008; 57: 1827-1835
  CrossrefPubMedGoogle Scholar
• 56 Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, Osinaga E, Rabinovich GA, Rivarola VA. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem 2008; 105: 381-390
  CrossrefPubMedGoogle Scholar
• 57 Kappler M, Rot S, Taubert H, Greither T, Bartel F, Dellas K, Hansgen G, Trott KR, Bache M. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther 2007; 14: 994-1001
  CrossrefPubMedGoogle Scholar
• 58 Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y, Dahiya R. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011; 71: 6208-6219
  CrossrefPubMedGoogle Scholar
• 59 Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005; 9: 360-372
  CrossrefPubMedGoogle Scholar
• 60 Pennati M, Binda M, Colella G, Zoppe M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004; 23: 386-394
  CrossrefPubMedGoogle Scholar
• 61 Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 2003; 10: 87-95
  CrossrefPubMedGoogle Scholar
• 62 Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R, Li Q, Xu P, Huang T. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 2007; 67: 8156-8163
  CrossrefPubMedGoogle Scholar
• 63 Peng J, He X, Wang K, Tan W, Li H, Xing X, Wang Y. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells. Nanomedicine 2006; 2: 113-120
  CrossrefPubMedGoogle Scholar
• 64 Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, Hirsch SA, Shepard PJ, Koo S, Murphy C, Glazer RI, Dean NM. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. Cancer Res 2006; 66: 2059-2066
  CrossrefPubMedGoogle Scholar
• 65 Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N, Sasamata M. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 2011; 17: 5423-5431
  CrossrefPubMedGoogle Scholar
• 66 Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 2012; 48: 763-771
  CrossrefPubMedGoogle Scholar
• 67 Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2012; 23: 968-973
  CrossrefPubMedGoogle Scholar
• 68 Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012; 118: 3128-3134
  CrossrefPubMedGoogle Scholar
• 69 Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, Thorstraten P, Andersen MH. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004; 3: 173-179
  PubMedGoogle Scholar
• 70 Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 2005; 48: 281-289
  CrossrefPubMedGoogle Scholar
• 71 Wust S, van den Brandt J, Tischner D, Kleiman A, Tuckermann JP, Gold R, Luhder F, Reichardt HM. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008; 180: 8434-8443
  PubMedGoogle Scholar
• 72 Okosieme OE, Parkes AB, Premawardhana LD, Thomas AW, Evans LM, Lazarus JH. Peripheral cytokine expression in autoimmune thyroiditis: effects of in vitro modulation by rosiglitazone and dexamethasone. Thyroid 2006; 16: 953-960
  CrossrefPubMedGoogle Scholar